Edmond DE Rothschild Holding S.A. Has $50.33 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Edmond DE Rothschild Holding S.A. reduced its Pfizer Inc. holdings by 5.7%, selling 119,934 shares in the first quarter, and now owns 1,986,176 shares valued at approximately $50.3 million.
• Other institutional investors, including Clark Capital Management and Bridgeway Capital Management, have also adjusted their positions in Pfizer, with some increasing their stake significantly.
• Pfizer reported a 10.3% increase in revenue year-over-year for the quarter, amounting to $14.65 billion, and beat EPS expectations with $0.78 per share compared to a consensus estimate of $0.58.

Edmond DE Rothschild Holding S.A. lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.7% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,986,176 shares of the biopharmaceutical company's stock after selling 119,934 shares during the period. Pfizer accounts for about 0.9% of Edmond DE Rothschild Holding S.A.'s portfolio, making the stock its 26th largest position. Edmond DE Rothschild Holding S.A.'s holdings in Pfizer were worth $50,330,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in PFE. Brighton Jones LLC boosted its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. Triumph Capital Management boosted its holdings in Pfizer by 20.0% in the fourth quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock valued at $273,000 after acquiring an additional 1,717 shares during the last quarter. Centiva Capital LP boosted its holdings in Pfizer by 75.2% in the fourth quarter. Centiva Capital LP now owns 16,875 shares of the biopharmaceutical company's stock valued at $448,000 after acquiring an additional 7,244 shares during the last quarter. Finally, Cornerstone Select Advisors LLC bought a new position in Pfizer in the fourth quarter valued at about $432,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Berenberg Bank cut their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Jefferies Financial Group increased their target price on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. HSBC cut their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Stock Up 1.3%

Shares of NYSE PFE traded up $0.32 during mid-day trading on Friday, reaching $24.86. 34,585,557 shares of the company's stock were exchanged, compared to its average volume of 34,757,608. The firm has a market capitalization of $141.31 billion, a price-to-earnings ratio of 13.22, a PEG ratio of 0.87 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $24.85 and a 200 day simple moving average of $24.36. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the firm posted $0.60 earnings per share. Pfizer's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.